Cor­rect­ed: Bench­Sci rais­es $70M Se­ries D for drug dis­cov­ery soft­ware; Zen­tal­is touts PhIb ovar­i­an can­cer da­ta

Cana­da’s Bench­Sci has raised $70 mil­lion in a Se­ries D round de­signed to scale its AI drug dis­cov­ery plat­form for sci­en­tists work­ing in pre­clin­i­cal re­search.

The com­pa­ny boasts thou­sands of clients for its soft­ware, in­clud­ing 16 of the top 20 phar­ma­ceu­ti­cal com­pa­nies. On the plat­form, re­searchers can get a di­gest of AI’s sum­ma­ry of med­ical, clin­i­cal and re­search da­ta — help­ing them spot bi­o­log­i­cal con­nec­tions and choose among thou­sands of op­tions with, say, a reagent or an­ti­body.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN